SARS-CoV-2 Antiviral Prescribing Gaps Among Non-Hospitalized High-Risk Adults.

Matthew E Levy, Evanette Burrows,Vanessa Chilunda,Pamala A Pawloski,Phillip R Heaton,Joseph Grzymski,Jason D Goldman, Lisa M McEwen,Dana Wyman,Andrew Dei Rossi,Hang Dai,Magnus Isaksson,Nicole L Washington,Tracy Basler, Kevin Tsan,Jason Nguyen,Jimmy Ramirez,Efren Sandoval,William Lee,James Lu,Shishi Luo

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America（2024）

引用 0|浏览11

暂无评分

摘要

Within a multi-state clinical cohort, SARS-CoV-2 antiviral prescribing patterns were evaluated from April 2022-June 2023 among non-hospitalized SARS-CoV-2-infected patients with risk factors for severe COVID-19. Among 3,247 adults, only 31.9% were prescribed an antiviral agent (87.6% nirmatrelvir/ritonavir, 11.9% molnupiravir, 0.5% remdesivir), highlighting the need to identify and address treatment barriers.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要